6 December 2010 -- Global Clinical Research Organisation (CRO), ClinTec International, has been ranked in the Deloitte UK Technology Fast 50 & Fast 500 EMEA. The awards, which are based on percentage revenue growth over a 5 year period, position and recognise ClinTec as number 46 in the top 50 fastest-growing technology companies in the UK and 226 in the 500 fastest growing in Europe, the Middle East and Africa. The Deloitte Technology Fast 50 is recognised as one of the UK's foremost technology award programmes. Moreover, the Technology Fast 500 EMEA programme, now into its tenth year, recognises all technology areas including companies in the private and public sectors. Both rank companies by percentage growth achieved over a five year period.
ClinTec, which generated a 738% growth rate over the course of the past five years, has grown organically since its inception by founder and CEO, Dr Rabinder Buttar, in 1997. The company now operates in over 40 countries worldwide, providing specialist clinical support services to clients including 11 of the top 25 pharmaceutical companies, plus innovative biotech and medical device organisations.
The official award ceremony took place on Thursday, 25 November 2010, at the Emirates Stadium in the UK.
Bobby Bal, Senior Director of Corporate Development, and previously a Management Consultant at Deloitte, commented: “Our placement of the rankings list is testament to the efforts of our committed staff around the world. Translating client challenges into flexible and innovative solutions has allowed us to compete at the top level in our sector within the EMEA marketplace. The principle of being completely client aligned is now allowing us to implement solutions in Asia Pacific and Latin America, driving further growth in our business”.
This achievement comes soon after ClinTec was named the 27th fastest growing UK private technology company in the Sunday Times Microsoft Tech Track 100 league table. In addition, ClinTec was shortlisted for Best CRO at the Scrip Awards held in November.
About ClinTec International
ClinTec International is a global contract clinical research organisation, established in 1997, by Dr Rabinder Buttar, the company’s President and CEO. ClinTec International has a presence in 40 developed and emerging countries, covering Western Europe, Central & Eastern Europe, the Middle East and North Africa, Central and South Africa, Latin America, India and the US.
In addition to ClinTec International’s vast expertise in oncology, the organisation has also conducted over 400 clinical trials in other therapeutic areas including anti-infectives, cardiology, dermatology, gastroenterology, neurology, respiratory medicine and rheumatology. ClinTec International excels in conducting clinical studies in diverse geographical locations, supported by a team of world-class project managers and clinical research associates. ClinTec International’s ‘fast, flexible and focused? approach to clinical research ensures an added advantage to the drug development process. The organisations range of services includes Clinical Monitoring and Project Management, Regulatory Affairs, Medical Writing, Data Management and Biostatistics, Global Clinical Resourcing, Quality Assurance, Drug Development Consultancy and Clinical Training courses.
For further information please contact:
Bobby Bal, Senior Director Corporate Development, ClinTec International Headquarters: +44 (0) 141 226 1120 or email@example.com.
For more information about ClinTec, please visit www.clintec.com
For media enquiries, contact:
Tristan Jervis, Associate Director, De Facto Communications: +44 (0) 207 861 3019 or firstname.lastname@example.org